Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 478

1.

The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.

Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, Dar AR, Wasserman T, Roach M, Lee JS, Andras E.

Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1143-9.

PMID:
10613306
2.

Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.

Komaki R, Scott CB, Sause WT, Johnson DH, Taylor SG 4th, Lee JS, Emami B, Byhardt RW, Curran WJ Jr, Dar AR, Cox JD.

Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):537-44.

PMID:
9336129
3.

Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.

Komaki R, Scott C, Lee JS, Urtasun RC, Byhardt RW, Emami B, Andras EJ, Asbell SO, Rotman M, Cox JD.

Am J Clin Oncol. 1997 Oct;20(5):435-40.

PMID:
9345325
4.
5.

Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.

Reboul F, Brewer Y, Vincent P, Chauvet B, Faure CF, Taulelle M.

Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):343-50.

PMID:
8635942
6.

Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.

Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W.

Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):548-57.

PMID:
12062596
7.

Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.

Werner-Wasik M, Scott C, Cox JD, Sause WT, Byhardt RW, Asbell S, Russell A, Komaki R, Lee JS.

Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1475-82.

PMID:
11121651
8.
9.

A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).

Choy H, Devore RF 3rd, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH.

Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):931-7.

PMID:
10863062
10.

A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.

Park J, Ahn YC, Kim H, Lee SH, Park SH, Lee KE, Lim DH, Park J, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K.

Lung Cancer. 2003 Nov;42(2):227-35.

PMID:
14568691
11.

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.

Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT, et al.

J Natl Cancer Inst. 1995 Feb 1;87(3):198-205.

PMID:
7707407
12.

Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.

Lee SW, Choi EK, Lee JS, Lee SD, Suh C, Kim SW, Kim WS, Ahn SD, Yi BY, Kim JH, Noh YJ, Kim SS, Koh Y, Kim DS, Kim WD.

Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):996-1004.

PMID:
12829135
13.

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR.

J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5.

PMID:
8780630
14.

Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer.

Schild SE, Stella PJ, Geyer SM, Bonner JA, Marks RS, McGinnis WL, Goetz SP, Kuross SA, Mailliard JA, Kugler JW, Schaefer PL, Jett JR.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):370-8.

PMID:
12243810
15.

Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04.

Komaki R, Scott C, Ettinger D, Lee JS, Fossella FV, Curran W, Evans RF, Rubin P, Byhardt RW.

Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):149-55.

PMID:
9212017
16.

Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.

Mirimanoff RO, Moro D, Bolla M, Michel G, Brambilla C, Mermillod B, Miralbell R, Alberto P.

Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):487-94.

PMID:
9806505
18.

Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.

Werner-Wasik M, Scott C, Graham ML, Smith C, Byhardt RW, Roach M 3rd, Andras EJ.

Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):327-31.

PMID:
10760427
19.

Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience.

Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW, Curran WJ.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):667-71. Epub 2005 May 31.

PMID:
15927409
20.

Supplemental Content

Support Center